cagrilintide vs cagrilintide/semaglutide

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Obesity

Shared mechanisms: Amylin receptor · Amylin/calcitonin receptor (dual) · full Obesity pipeline

cagrilintide

Developed by Novo Nordisk

Phase 3 in Obesitypeptide
Reliable signal

NCT03856047 · Phase 2 · completed

The trial randomized participants to five active doses, a pooled placebo, and an active liraglutide comparator arm, with quadruple-blinding (participant, care provider, investigator, and outcomes assessor all masked) and roughly 100 participants per arm. The primary endpoint, percent change in body weight at 26 weeks, is the regulator-accepted physiological measure for obesity trials, and every cagrilintide dose showed a statistically significant weight-loss advantage over placebo (p-values ranging from 0.0002 to <.0001), so the primary comparison was clearly met in the favorable direction.

Next expected readout: January 2027 · NCT07411560 (registry estimate)

Reported efficacy

Change in Body Weight (%) (From baseline (week 0) to week 26): Change in Body Weight (%) (From baseline (week 0) to week 26): Cagrilintide 0.3 mg -6.1% (Standard Deviation 3.9) | Cagrilintide 0.6 mg -6.9% (Standard Deviation 5.4) | Cagrilintide 1.2 mg -8.5% (Standard Deviation 5.4) | Cagrilintide 2.4 mg -9.5% (Standard Deviation 6.2) | Cagrilintide 4.5 mg -10.8% (Standard Deviation 5.5) vs Liraglutide 3.0 mg -8.5% (Standard Deviation 5.6) | Pooled Placebo -3% (Standard Deviation 5.2) (met)

Result source: NCT03856047

cagrilintide/semaglutide · CagriSema

Developed by Novo Nordisk

Phase 3 in Obesitypeptide
Reliable signal

NCT05394519 · Phase 3 · completed

This was a large, randomized, quadruple-blind, placebo-controlled trial in 1,200 patients using percentage body weight change, the standard efficacy measure for obesity treatment. CagriSema reduced body weight by 13.7% versus 3.4% on placebo, a 10.4-percentage-point difference (p<0.001), meeting the primary endpoint.

Next expected readout: March 2027 · NCT07011667 (registry estimate)

Reported efficacy

Relative change in body weight (From baseline (week 0) to end of treatment (week 68)); Achievement of greater than or equal to (≥) 5% weight reduction (From baseline (week 0) to end of treatment (week 68)): Change in body weight at week 68: -13.7% with CagriSema vs -3.4% with placebo; estimated difference -10.4 percentage points (p<0.001) (met)

Result source: NCT05394519

Results for Obesity

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointcagrilintidecagrilintide/​semaglutide
Body weight, % change-10.8% vs -3%−7.8 vs placebo4.5 mg · wk 26 · n 97NCT03856047
4 other results
  • -9.5% vs -3% 2.4 mg · wk 26 · n 99 · Phase 2 · primary NCT03856047
  • -8.5% vs -3% 1.2 mg · wk 26 · n 98 · Phase 2 · primary NCT03856047
  • -6.9% vs -3% 0.6 mg · wk 26 · n 97 · Phase 2 · primary NCT03856047
  • -6.1% vs -3% 0.3 mg · wk 26 · n 96 · Phase 2 · primary NCT03856047
-13.7% vs -3.4%a−10.3 vs placebowk 68NCT05394519
1 other result
  • -18.4% vs -11.9% wk 68 · Phase 3 · primary NCT05813925
Weight loss of 5% or more88.7% vs 30.9%+57.8 vs placebo4.5 mg · wk 26 · n 80NCT03856047
4 other results
  • 74.1% vs 30.9% 2.4 mg · wk 26 · n 80 · Phase 2 · secondary NCT03856047
  • 75.8% vs 30.9% 1.2 mg · wk 26 · n 72 · Phase 2 · secondary NCT03856047
  • 62.0% vs 30.9% 0.6 mg · wk 26 · n 82 · Phase 2 · secondary NCT03856047
  • 57.5% vs 30.9% 0.3 mg · wk 26 · n 83 · Phase 2 · secondary NCT03856047
—Not posted · NCT05996848
Weight loss of 10% or more53.5% vs 10.4%+43.1 vs placebo4.5 mg · wk 26 · n 80NCT03856047
4 other results
  • 44.0% vs 10.4% 2.4 mg · wk 26 · n 80 · Phase 2 · secondary NCT03856047
  • 35.8% vs 10.4% 1.2 mg · wk 26 · n 72 · Phase 2 · secondary NCT03856047
  • 24.1% vs 10.4% 0.6 mg · wk 26 · n 82 · Phase 2 · secondary NCT03856047
  • 15.3% vs 10.4% 0.3 mg · wk 26 · n 83 · Phase 2 · secondary NCT03856047
—Not posted · NCT05996848
Waist circumference, change (cm)-9.5 vs -3.4−6.1 vs placebo4.5 mg · wk 26 · n 97NCT03856047
4 other results
  • -8.1 vs -3.4 2.4 mg · wk 26 · n 99 · Phase 2 · secondary NCT03856047
  • -7.7 vs -3.4 1.2 mg · wk 26 · n 98 · Phase 2 · secondary NCT03856047
  • -6.2 vs -3.4 0.6 mg · wk 26 · n 97 · Phase 2 · secondary NCT03856047
  • -6.2 vs -3.4 0.3 mg · wk 26 · n 96 · Phase 2 · secondary NCT03856047
—Not posted · NCT05996848

Body weight, % change

cagrilintide
-10.8% vs -3%−7.8 vs placebo4.5 mg · wk 26 · n 97NCT03856047
4 other results
  • -9.5% vs -3% 2.4 mg · wk 26 · n 99 · Phase 2 · primary NCT03856047
  • -8.5% vs -3% 1.2 mg · wk 26 · n 98 · Phase 2 · primary NCT03856047
  • -6.9% vs -3% 0.6 mg · wk 26 · n 97 · Phase 2 · primary NCT03856047
  • -6.1% vs -3% 0.3 mg · wk 26 · n 96 · Phase 2 · primary NCT03856047
cagrilintide/​semaglutide
-13.7% vs -3.4%a−10.3 vs placebowk 68NCT05394519
1 other result
  • -18.4% vs -11.9% wk 68 · Phase 3 · primary NCT05813925

Weight loss of 5% or more

cagrilintide
88.7% vs 30.9%+57.8 vs placebo4.5 mg · wk 26 · n 80NCT03856047
4 other results
  • 74.1% vs 30.9% 2.4 mg · wk 26 · n 80 · Phase 2 · secondary NCT03856047
  • 75.8% vs 30.9% 1.2 mg · wk 26 · n 72 · Phase 2 · secondary NCT03856047
  • 62.0% vs 30.9% 0.6 mg · wk 26 · n 82 · Phase 2 · secondary NCT03856047
  • 57.5% vs 30.9% 0.3 mg · wk 26 · n 83 · Phase 2 · secondary NCT03856047
cagrilintide/​semaglutide
—Not posted · NCT05996848

Weight loss of 10% or more

cagrilintide
53.5% vs 10.4%+43.1 vs placebo4.5 mg · wk 26 · n 80NCT03856047
4 other results
  • 44.0% vs 10.4% 2.4 mg · wk 26 · n 80 · Phase 2 · secondary NCT03856047
  • 35.8% vs 10.4% 1.2 mg · wk 26 · n 72 · Phase 2 · secondary NCT03856047
  • 24.1% vs 10.4% 0.6 mg · wk 26 · n 82 · Phase 2 · secondary NCT03856047
  • 15.3% vs 10.4% 0.3 mg · wk 26 · n 83 · Phase 2 · secondary NCT03856047
cagrilintide/​semaglutide
—Not posted · NCT05996848

Waist circumference, change (cm)

cagrilintide
-9.5 vs -3.4−6.1 vs placebo4.5 mg · wk 26 · n 97NCT03856047
4 other results
  • -8.1 vs -3.4 2.4 mg · wk 26 · n 99 · Phase 2 · secondary NCT03856047
  • -7.7 vs -3.4 1.2 mg · wk 26 · n 98 · Phase 2 · secondary NCT03856047
  • -6.2 vs -3.4 0.6 mg · wk 26 · n 97 · Phase 2 · secondary NCT03856047
  • -6.2 vs -3.4 0.3 mg · wk 26 · n 96 · Phase 2 · secondary NCT03856047
cagrilintide/​semaglutide
—Not posted · NCT05996848
  1. a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
  2. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  3. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. cagrilintide: 3 of 4 rows · cagrilintide/semaglutide: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metriccagrilintidecagrilintide/​semaglutide
Dropout rate
6.9%4.5 mg
NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2
show 4 more results
1%2.4 mg
NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2
3.9%1.2 mg
NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2
3%0.6 mg
NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2
4%0.3 mg
NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2
—
Discontinued due to AEs
—4.5 mg
NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2
show 4 more results
—2.4 mg
NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2
—1.2 mg
NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2
—0.6 mg
NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2
—0.3 mg
NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2
—
Serious AEs
4%4.5 mg
NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2
show 4 more results
2.9%2.4 mg
NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2
6.9%1.2 mg
NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2
2%0.6 mg
NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2
5.9%0.3 mg
NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2
—
Most frequent reported AEs
4.5 mg
nausea 46.5% (placebo 17.8%)
constipation 20.8% (placebo 6.9%)
fatigue 19.8% (placebo 3%)
NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2
show 4 more results
2.4 mg
nausea 31.4% (placebo 17.8%)
diarrhoea 17.6% (placebo 8.9%)
constipation 16.7% (placebo 6.9%)
NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2
1.2 mg
nausea 36.3% (placebo 17.8%)
nasopharyngitis 12.7% (placebo 9.9%)
headache 10.8% (placebo 11.9%)
NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2
0.6 mg
nausea 27% (placebo 17.8%)
diarrhoea 10% (placebo 8.9%)
constipation 9% (placebo 6.9%)
NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2
0.3 mg
nausea 19.8% (placebo 17.8%)
diarrhoea 14.9% (placebo 8.9%)
constipation 10.9% (placebo 6.9%)
NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2
—

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

cagrilintide

Weight Loss 5% 88.74% (n=80) vs 30.9% (n=79) placebo @ 26wk4.5 mg
responder rate · % of participants
NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2
show 4 more results
74.12% (n=80) vs 30.9% (n=79) placebo @ 26wk2.4 mg
NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2
75.84% (n=72) vs 30.9% (n=79) placebo @ 26wk1.2 mg
NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2
61.98% (n=82) vs 30.9% (n=79) placebo @ 26wk0.6 mg
NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2
57.47% (n=83) vs 30.9% (n=79) placebo @ 26wk0.3 mg
NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2
Weight Loss 10% 53.49% (n=80) vs 10.44% (n=79) placebo @ 26wk4.5 mg
responder rate · % of participants
NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2
show 4 more results
43.97% (n=80) vs 10.44% (n=79) placebo @ 26wk2.4 mg
NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2
35.79% (n=72) vs 10.44% (n=79) placebo @ 26wk1.2 mg
NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2
24.06% (n=82) vs 10.44% (n=79) placebo @ 26wk0.6 mg
NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2
15.28% (n=83) vs 10.44% (n=79) placebo @ 26wk0.3 mg
NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2
Weight -11.8 vs -3.2 placebo kg @ 26wk4.5 mg
absolute change · kg
NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2
show 4 more results
-10.1 vs -3.2 placebo kg @ 26wk2.4 mg
NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2
-9 vs -3.2 placebo kg @ 26wk1.2 mg
NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2
-7.1 vs -3.2 placebo kg @ 26wk0.6 mg
NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2
-6.6 vs -3.2 placebo kg @ 26wk0.3 mg
NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2
Waist Circumference Change -9.5 vs -3.4 placebo cm @ 26wk4.5 mg
absolute change · cm
NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2
show 4 more results
-8.1 vs -3.4 placebo cm @ 26wk2.4 mg
NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2
-7.7 vs -3.4 placebo cm @ 26wk1.2 mg
NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2
-6.2 vs -3.4 placebo cm @ 26wk0.6 mg
NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2
-6.2 vs -3.4 placebo cm @ 26wk0.3 mg
NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2
HbA1c -0.1% (n=95) vs -0.1% (n=94) placebo @ 26wk4.5 mg
absolute change · percentage points
NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2
show 4 more results
-0.1% (n=99) vs -0.1% (n=94) placebo @ 26wk2.4 mg
NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2
-0.1% (n=95) vs -0.1% (n=94) placebo @ 26wk1.2 mg
NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2
-0.1% (n=97) vs -0.1% (n=94) placebo @ 26wk0.6 mg
NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2
0% (n=93) vs -0.1% (n=94) placebo @ 26wk0.3 mg
NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2

Type 2 Diabetes

Shared mechanisms: Amylin receptor · Amylin/calcitonin receptor (dual) · full Type 2 Diabetes pipeline

cagrilintide

Developed by Novo Nordisk

Phase 3 in Type 2 Diabetespeptide
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: May 2027 · NCT07220759 (registry estimate)

No aligned efficacy figure on record for this race.

cagrilintide/semaglutide · CagriSema

Developed by Novo Nordisk

Phase 3 in Type 2 Diabetespeptide
Reliable signal

NCT05394519 · Phase 3 · completed

This was a large, randomized, quadruple-blind, placebo-controlled trial in 1,200 patients using percentage body weight change, the standard efficacy measure for obesity treatment. CagriSema reduced body weight by 13.7% versus 3.4% on placebo, a 10.4-percentage-point difference (p<0.001), meeting the primary endpoint.

Next expected readout: June 2027 · NCT07817251 (registry estimate)

Reported efficacy

Relative change in body weight (From baseline (week 0) to end of treatment (week 68)); Achievement of greater than or equal to (≥) 5% weight reduction (From baseline (week 0) to end of treatment (week 68)): Change in body weight at week 68: -13.7% with CagriSema vs -3.4% with placebo; estimated difference -10.4 percentage points (p<0.001) (met)

Result source: NCT05394519

Results for Type 2 Diabetes

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointcagrilintidecagrilintide/​semaglutide
HbA1c, change—Not posted · NCT05394519—Not posted · NCT05394519
Body weight, change (kg)—Not posted · NCT05394519—Not posted · NCT05394519
HbA1c below 7%—Not posted · NCT05394519—Not posted · NCT05394519
Fasting plasma glucose, change—Not posted · NCT05394519—Not posted · NCT05394519
3-point MACE (% with event)—Not posted · NCT05394519—Not posted · NCT05394519

HbA1c, change

cagrilintide
—Not posted · NCT05394519
cagrilintide/​semaglutide
—Not posted · NCT05394519

Body weight, change (kg)

cagrilintide
—Not posted · NCT05394519
cagrilintide/​semaglutide
—Not posted · NCT05394519

HbA1c below 7%

cagrilintide
—Not posted · NCT05394519
cagrilintide/​semaglutide
—Not posted · NCT05394519

Fasting plasma glucose, change

cagrilintide
—Not posted · NCT05394519
cagrilintide/​semaglutide
—Not posted · NCT05394519

3-point MACE (% with event)

cagrilintide
—Not posted · NCT05394519
cagrilintide/​semaglutide
—Not posted · NCT05394519
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

cagrilintide: registry results are on file for Type 2 Diabetes, but their comparison mappings are not yet available.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

cagrilintide/semaglutide

Weight -13.7% vs -3.4% placebo @ 68wk
percent change · % of baseline
NCT05394519 · Phase 3 · sponsor-reported, not registry data

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: cagrilintide's landscape · cagrilintide/semaglutide's landscape